UXT

Across TCGA pan-cancer cohorts, UXT mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of UXT’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where UXT mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types UXT is over-expressed in tumor.

HNSC, LUAD, and LSCC are the cancer types where UXT tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UXT mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.240	<.001	11	view →
LUAD	All	II,III,IV	+0.287	<.001	9	view →
LSCC	Male	II,III,IV	+0.281	<.001	7	view →
OV	All	All	+0.432	.028	2	view →
PDAC	Female	III,IV	+0.320	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

UXT–HNSC

Open the HNSC breakdown →